AtriCure CTO sells 3,657 shares at $55

AtriCure’s Chief Technical Officer sold 3,657 shares under a pre-arranged Rule 10b5-1 trading plan and continues to hold 147,264 shares directly.

Available on EDGAR 09/10/2026 - 09:18 AM EDT Accepted by SEC EDGAR 09/10/2026 - 09:18 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

AtriCure, Inc. (ATRC) reported that Chief Technical Officer Salvatore Privitera sold 3,657 shares of common stock on September 8, 2026 at a price of $55.00 per share in a sale described as an open market or private transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2026, indicating it was pre-arranged. Following this transaction, Privitera directly holds 147,264 shares of AtriCure common stock.

Insider Trade Summary 10b5-1

Net Seller: 3,657 shares

Net Sell 1 txn

Insider Privitera Salvatore

Role Chief Technical Officer

Sold 3,657 shs ($201K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	3,657	$55.00	$201K

Holdings After Transaction: Common Stock — 147,264 shares (Direct)

Footnotes (1)

1. F1. These shares were sold pursuant to a 10b5-1 trading plan adopted on February, 20, 2026.

Key Figures

Shares sold: 3,657 shares Sale price per share: $55.00 per share Shares held after transaction: 147,264 shares +3 more

6 metrics

Shares sold 3,657 shares Common stock sale by Chief Technical Officer on September 8, 2026

Sale price per share $55.00 per share Price for the 3,657 shares sold on September 8, 2026

Shares held after transaction 147,264 shares Direct holdings of Salvatore Privitera following the sale

Net shares sold 3,657 shares Net change in common stock holdings reported in this Form 4

Transaction date September 8, 2026 Date of the reported sale of common stock

10b5-1 plan adoption date February 20, 2026 Adoption date of the trading plan under which the sale occurred

Key Terms

Rule 10b5-1 trading plan, open market or private transaction, Form 4

3 terms

Rule 10b5-1 trading plan regulatory

"These shares were sold pursuant to a 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open market or private transaction financial

"Sale in open market or private transaction"

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AtriCure (ATRC) disclose in this Form 4?

AtriCure disclosed that Chief Technical Officer Salvatore Privitera sold 3,657 shares of common stock on September 8, 2026 at $55.00 per share in an open market or private transaction under a Rule 10b5-1 trading plan.

How many AtriCure (ATRC) shares does Salvatore Privitera hold after the reported sale?

After the reported transaction, Salvatore Privitera directly holds 147,264 shares of AtriCure common stock, as stated in the Form 4 filing.

Was the AtriCure (ATRC) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the 3,657-share sale on September 8, 2026 was made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2026, and the Rule 10b5-1 checkbox is affirmed.

What was the sale price for the AtriCure (ATRC) shares in this Form 4?

The reported sale price was $55.00 per share for the 3,657 shares of AtriCure common stock sold by Chief Technical Officer Salvatore Privitera on September 8, 2026.

What role does the insider hold at AtriCure (ATRC) in this Form 4?

The reporting person, Salvatore Privitera, is identified as AtriCure’s Chief Technical Officer in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Privitera Salvatore

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OHIO 45040-9695

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		S		3,657(1)	D	$55	147,264	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold pursuant to a 10b5-1 trading plan adopted on February, 20, 2026.

Remarks:

	/s/ Salvatore Privitera	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)